α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.
IF 1 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Kritika Subramanian, Judith Stangl-Kremser, Lady Sawoszczyk, Vasilios Avlonitis, Andrew Gernerd, Kyla Nixon, Michael Zgaljardic, Scott Tagawa, Neil Bander, Joseph R Osborne
{"title":"α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.","authors":"Kritika Subramanian, Judith Stangl-Kremser, Lady Sawoszczyk, Vasilios Avlonitis, Andrew Gernerd, Kyla Nixon, Michael Zgaljardic, Scott Tagawa, Neil Bander, Joseph R Osborne","doi":"10.2967/jnmt.122.265166","DOIUrl":null,"url":null,"abstract":"<p><p>The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop <sup>225</sup>Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.122.265166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.